Davide Noto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4955340/publications.pdf

Version: 2024-02-01

		182225	223390
92	2,763	30	49
papers	citations	h-index	g-index

97	97	97	3982
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	LIfeSTyle versus Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	3
2	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients. Atherosclerosis, 2022, 347, 63-67.	0.4	5
3	Comparison of two polygenic risk scores to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects. Journal of Clinical Lipidology, 2022, 16, 530-537.	0.6	3
4	Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. Endocrine, 2021, 71, 344-350.	1.1	9
5	DeepSRE: Identification of sterol responsive elements and nuclear transcription factors Y proximity in human DNA by Convolutional Neural Network analysis. PLoS ONE, 2021, 16, e0247402.	1.1	1
6	Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life, 2021, 11, 315.	1.1	8
7	Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia. Internal Medicine Journal, 2021, 51, 585-590.	0.5	1
8	rs629301 CELSR2 polymorphism confers a ten-year equivalent risk of critical stenosis assessed by coronary angiography. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1542-1547.	1.1	7
9	Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases. Life, 2021, 11, 581.	1.1	11
10	PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study. Atherosclerosis, 2020, 292, 209-214.	0.4	6
11	Automated untargeted stable isotope assisted lipidomics of liver cells on high glucose shows alteration of sphingolipid kinetics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158656.	1.2	1
12	Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. Current Medicinal Chemistry, 2020, 27, 3773-3783.	1.2	3
13	Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1068-1076.	1.1	10
14	Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 822-829.	1.1	28
15	Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred. Journal of Clinical Lipidology, 2018, 12, 145-151.	0.6	8
16	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
17	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. Cardiovascular Research, 2018, 114, 1595-1604.	1.8	9
18	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.4	131

#	Article	IF	Citations
19	Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. Journal of Clinical Lipidology, 2017, 11, 272-281.e8.	0.6	18
20	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Advances in Therapy, 2017, 34, 1200-1210.	1.3	56
21	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
22	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
23	Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat Î²-Cells. Direct Effect of Oxidative Stress. Scientific Reports, 2017, 7, 11863.	1.6	59
24	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: AÂcomparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. Journal of Clinical Lipidology, 2017, 11, 1234-1242.	0.6	34
25	Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterolâ€“diabetes connection? A systematic review of literature. Acta Diabetologica, 2017, 54, 111-122.	1.2	19
26	FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheimer's disease. Analytical and Bioanalytical Chemistry, 2016, 408, 2215-2226.	1.9	4
27	Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 371-379.	1.2	5
28	Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particles trapping to cell surface proteoglycans in a liver hepatoma cell model. Atherosclerosis, 2016, 246, 50-56.	0.4	16
29	Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic endâ€stage renal disease patients. Hemodialysis International, 2015, 19, 360-367.	0.4	5
30	Role of Nutraceuticals in Hypolipidemic Therapy. Frontiers in Cardiovascular Medicine, 2015, 2, 22.	1.1	22
31	The pathophysiology of intestinal lipoprotein production. Frontiers in Physiology, 2015, 6, 61.	1.3	33
32	Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. Atherosclerosis, 2015, 241, 79-86.	0.4	55
33	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. Atherosclerosis, 2015, 239, 209-217.	0.4	17
34	Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scandinavian Journal of Gastroenterology, 2015, 50, 347-354.	0.6	20
35	Exome Sequencing in Suspected Monogenic Dyslipidemias. Circulation: Cardiovascular Genetics, 2015, 8, 343-350.	5.1	45
36	Effects of Steatosis on Hepatic Hemodynamics in Patients with Metabolic Syndrome. Ultrasound in Medicine and Biology, 2015, 41, 1545-1552.	0.7	11

#	Article	IF	Citations
37	Lipid Peroxidation, Nitric Oxide Metabolites, and Their Ratio in a Group of Subjects with Metabolic Syndrome. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-8.	1.9	15
38	Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk. Current Atherosclerosis Reports, 2014, 16, 414.	2.0	20
39	Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis, 2013, 227, 342-348.	0.4	128
40	Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetologica, 2013, 50, 241-249.	1.2	48
41	Protein oxidation in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2013, 7, 38-41.	1.8	12
42	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. Journal of Lipid Research, 2013, 54, 3481-3490.	2.0	76
43	The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. Diabetes Care, 2013, 36, 2850-2856.	4.3	51
44	A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2021-2025.	1.1	73
45	Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Lowâ€HDL Phenotype. Journal of the American Heart Association, 2013, 2, e000063.	1.6	28
46	Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 805-809.	1.1	80
47	Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. Journal of Translational Medicine, 2012, 10, 235.	1.8	35
48	Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2012, 6, 132-135.	1.8	21
49	Clinical utility of novel biomarkers for cardiovascular disease risk stratification. Internal and Emergency Medicine, 2012, 7, 263-270.	1.0	5
50	Statin therapy in patients with aortic stenosis after the ASTRONOMER trial: is there still any space?. Internal and Emergency Medicine, 2012, 7, 35-36.	1.0	2
51	Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study. Acta Diabetologica, 2012, 49, 145-151.	1.2	10
52	Searching for wheat plants with low toxicity in celiac disease: Between direct toxicity and immunologic activation. Digestive and Liver Disease, 2011, 43, 34-39.	0.4	46
53	Plasma non-cholesterol sterols in primary hypobetalipoproteinemia. Atherosclerosis, 2011, 216, 409-413.	0.4	8
54	Lipase maturation factor 1 is required for endothelial lipase activity. Journal of Lipid Research, 2011, 52, 1162-1169.	2.0	21

#	Article	IF	Citations
55	Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. Metabolism: Clinical and Experimental, 2010, 59, 463-467.	1.5	21
56	Plasma Nonâ€“cholesterol Sterols: A Useful Diagnostic Tool in Pediatric Hypercholesterolemia. Pediatric Research, 2010, 67, 200-204.	1.1	15
57	The production of 85kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apob gene occurs by ALLN-inhibitable protease cleavage during translocation. Biochemical and Biophysical Research Communications, 2010, 398, 665-670.	1.0	6
58	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis, 2010, 208, 177-182.	0.4	74
59	A novel putative interactor for the low density lipoprotein receptor cytoplasmic domain. Molecular Medicine Reports, 2010, 3, 341-5.	1.1	0
60	Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4584-4590.	1.8	52
61	C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clinical Biochemistry, 2009, 42, 1713-1718.	0.8	30
62	Novel mutations of CETP gene in Italian subjects with hyeralphalipoproteinemia. Atherosclerosis, 2009, 204, 202-207.	0.4	26
63	Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. Atherosclerosis, 2009, 206, 193-198.	0.4	22
64	The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: Results of a 15 years follow-up in a Mediterranean population. Atherosclerosis, 2008, 197, 147-153.	0.4	42
65	Clinical symptoms in celiac patients on a gluten-free diet. Scandinavian Journal of Gastroenterology, 2008, 43, 1315-1321.	0.6	20
66	Molecular diagnosis of hypobetalipoproteinemia: An ENID review. Atherosclerosis, 2007, 195, e19-e27.	0.4	152
67	A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 677-681.	1.1	125
68	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thrombosis and Haemostasis, 2007, 98, 1362-1367.	1.8	15
69	Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins. Free Radical Biology and Medicine, 2007, 43, 1255-1262.	1.3	110
70	Multiple food hypersensitivity as a cause of refractory chronic constipation in adults. Scandinavian Journal of Gastroenterology, 2006, 41, 498-504.	0.6	26
71	Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis, 2006, 186, 433-440.	0.4	97
72	Unexplained Elevated Serum Pancreatic Enzymes: A Reason to Suspect Celiac Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 455-459.	2.4	32

#	Article	IF	Citations
73	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. Metabolism: Clinical and Experimental, 2006, 55, 662-668.	1.5	19
74	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. Metabolism: Clinical and Experimental, 2006, 55, 1308-1316.	1.5	15
75	Food intolerance and chronic constipation: manometry and histology study. European Journal of Gastroenterology and Hepatology, 2006, 18, 143-150.	0.8	39
76	RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. International Journal of Molecular Medicine, 2006, 18, 449.	1.8	6
77	Analysis of sterols by high-performance liquid chromatography/mass spectrometry combined with chemometrics. Rapid Communications in Mass Spectrometry, 2006, 20, 2433-2440.	0.7	35
78	Chronic constipation and food intolerance: A model of proctitis causing constipation. Scandinavian Journal of Gastroenterology, 2005, 40, 33-42.	0.6	46
79	Cystatin C levels are decreased in acute myocardial infarction. International Journal of Cardiology, 2005, 101, 213-217.	0.8	28
80	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 361-367.	1.1	11
81	A Novel Mutation of the DHCR7 Gene in a Sicilian Compound Heterozygote with Smith-Lemli-Opitz Syndrome. , 2005, 9, 201.		2
82	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. European Journal of Endocrinology, 2004, 150, 831-836.	1.9	0
83	Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. International Journal of Biochemistry and Cell Biology, 2004, 36, 1297-1305.	1.2	8
84	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. Clinica Chimica Acta, 2003, 328, 91-97.	0.5	3
85	Nutritional Characteristics of a Rural Southern Italy Population: The Ventimiglia di Sicilia Project. Journal of the American College of Nutrition, 2002, 21, 523-529.	1.1	30
86	Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. Neuroscience Letters, 2002, 335, 147-149.	1.0	40
87	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. American Journal of Cardiology, 2002, 89, 460-462.	0.7	17
88	Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. Kidney International, 1999, 55, 2433-2439.	2.6	15
89	Lipoprotein Profile and High-Density Lipoproteins: Subfractions Distribution in Centenarians. Gerontology, 1998, 44, 106-110.	1.4	22
90	Organ Loci of Catabolism of Short Truncations of ApoB. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1032-1038.	1.1	21

#	Article	IF	Citations
91	A new apolipoprotein B truncation (apo B-43.7) in familial hypobetalipoproteinemia: Genetic and metabolic studies. Metabolism: Clinical and Experimental, 1996, 45, 1296-1304.	1.5	17
92	Familial Hypobetalipoproteinemia Is Not Associated With Low Levels of Lipoprotein(a). Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2165-2175.	1.1	13